435 related articles for article (PubMed ID: 17625575)
1. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
2. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
Francis SH; Morris GZ; Corbin JD
Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
5. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
Bella AJ; Deyoung LX; Al-Numi M; Brock GB
Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
[TBL] [Abstract][Full Text] [Related]
6. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
7. PDE5 inhibitors: are there differences?
Carson CC
Can J Urol; 2006 Feb; 13 Suppl 1():34-9. PubMed ID: 16526979
[TBL] [Abstract][Full Text] [Related]
8. [Update of PDE5 inhibitors as treatment of ED].
Lu YN; Chen B
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
12. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
Wright PJ
Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
[TBL] [Abstract][Full Text] [Related]
13. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
14. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Roumeguère T; Sternon J; Schulman CC
Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
[TBL] [Abstract][Full Text] [Related]
15. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.
Burnett AL
J Androl; 2008; 29(1):3-14. PubMed ID: 17942972
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase 5 mechanisms and therapeutic applications.
Burnett AL
Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
[TBL] [Abstract][Full Text] [Related]
17. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences.
Greco EA; Spera G; Aversa A
Eur Urol; 2006 Nov; 50(5):940-7. PubMed ID: 16979814
[TBL] [Abstract][Full Text] [Related]
18. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
19. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
20. PDE5 inhibitors: looking beyond ED.
Jackson G
Int J Clin Pract; 2003 Apr; 57(3):159-60. PubMed ID: 12723713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
